Vanta Bioscience Ltd (BSE: 540729) is a Secunderabad, Telangana-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹15 Cr, it ranks #4,836 by market cap among the 6,137 Indian listed companies on FinBizNet, and #10 of 10 in Life Sciences Tools and Services. At ₹20.40 (as of 25 Oct 2026), the share price is 29.7% below its 52-week high of ₹29.00 and 38.7% above its 52-week low of ₹14.71. The share price is down 20.2% over one year and down 19.3% over three months.
| Current Price | ₹20.40 |
|---|---|
| Market Cap | ₹15 Cr |
| BSE Code | 540729 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | 136 |
| Return on Equity | 0.87% |
| Return on Assets | 0.64% |
| 52-Week Range | ₹14.71 – ₹29.00 |
| 1-Year Price Change | -20.2% |
| 3-Month Price Change | -19.3% |
| Beta (1Y) | 0.2 |
| Headquarters | Secunderabad, Telangana |
| Website | www.vantabio.com |
Vanta Bioscience Limited, together with its subsidiaries, operates as a preclinical contract research organization in India. The company offers a range of services in method development, validation, impurity profiling, impurity isolation, characterization, certification and evaluation, mammalian and genetic toxicology, drug metabolism, pharmacokinetics, and bio-analysis during the preclinical stage of drug development. It also provides testing services for agrochemicals and chemicals, such as physico-chemical testing; sub-acute, sub-chronic, and chronic; toxicokinetics assessment, CoA and dose formulation analysis, 5 batch analysis, and studies on behavior in water, soil and air, bioaccumulation, as well as acute 6 pack, carcinogenicity, genetic toxicity, DART, eco-toxicity, and alternative to animal studies. In addition, it offers diet formulation services, which include starter material processing, proximate and composition analysis, diet balancing and formulation, irradiation, and p
1. Full Service Preclinical Contract Research Organization-This segment operates as a preclinical contract research organization. It offers preclinical safety assessment services for clients from pharmaceutical, medical device, nutraceutical, feed additive, biotech, agrochemical, cosmetic, and chemical industries.
1. Full Service Preclinical Contract Research Organization-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Indegene Ltd | ₹14,413 Cr | 35.2 | 13.94% | ₹1,063 Cr | +5.9% |
| Suven Life Sciences Ltd. | ₹8,583 Cr | -24 | -78.80% | ₹4 Cr | +30.6% |
| Vimta Labs Ltd | ₹2,338 Cr | 29.3 | 18.55% | ₹109 Cr | -32.5% |
| Tarsons Products Limited | ₹1,762 Cr | 117.2 | 2.26% | ₹110 Cr | +3.3% |
| Bilcare Ltd. | ₹224 Cr | 122.4 | -5.21% | — | — |
| Brooks Laboratories Ltd. | ₹199 Cr | 8.1 | 22.28% | ₹23 Cr | -53.0% |
| Jeevan Scientific Technology Ltd | ₹178 Cr | 130.4 | 1.68% | — | +34.0% |
| Vivo Bio Tech Ltd. | ₹31 Cr | -16.6 | -2.00% | ₹14 Cr | -55.7% |
| Vanta Bioscience Ltd | ₹15 Cr | 136 | 0.87% | — | -20.2% |
Listed by market capitalisation. Ratios are shown for context only.
Vanta Bioscience Ltd is trading at ₹20.40, with a market capitalisation of ₹15 Cr.
Vanta Bioscience Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Vanta Bioscience Ltd has a P/E of 136 and a return on equity of 0.87%.
Vanta Bioscience Ltd is listed on the BSE under the scrip code 540729.
Vanta Bioscience Ltd's share price is down 20.2% over one year and down 19.3% over three months. Its 52-week range is ₹14.71 to ₹29.00.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.